在s-DAPK-1的分析:从结构到功能和调节
Lilian Makgoo1, Salerwe Mosebi2, Zukile Mbita1
1Department of Biochemistry, Microbiology and Biotechnology, University of Limpopo, Private Bag X1106, Sovenga 0727, South Africa.
Current issues in molecular biology
|July 23, 2025
概括
这项研究以计算方式研究了s-DAPK-1,这是DAPK-1的替代拼接变体,揭示了其microRNA点,稳定的3D结构以及与参与瘤进展和基因调节的蛋白质的相互作用.
科学领域:
- 分子生物学分子生物学
- 生物信息学是一种生物信息学.
- 结构生物学 结构生物学
背景情况:
- DAPK-1参与细胞存活,细胞亡和自.
- 替代拼接变体s-DAPK-1的具体作用尚不清楚.
- 关于s-DAPK-1的调节,相互作用,功能和结构的数据有限.
研究的目的:
- 通过预测其微RNA标来阐明s-DAPK-1的调节.
- 确定s-DAPK-1的3D结构,物理化学和热力学特性.
- 为了确定s-DAPK-1的相互作用伙伴,并预测其分子功能.
主要方法:
- 使用生物信息学工具和Web服务器 (例如Phyre2,TarBase,蛋白质数据库).
- 使用TarBase. 预测的微RNA目标.
- 计算预测了3D结构,稳定性和相互作用蛋白质.
主要成果:
- 确定了针对s-DAPK-1的特定微RNA.
- s-DAPK-1表现出一个稳定的3D结构,其中40%的α螺旋和4%的β链.
- s-DAPK-1具有热稳定性,并与参与瘤进展和基因调节的蛋白质相互作用,包括蛋白和H2B2E.
结论:
- s-DAPK-1的调节受特定的微RNA的影响.
- 这种蛋白质具有稳定,热稳定的结构.
- s-DAPK-1 可能在代谢过程,核酸结合和通过蛋白质相互作用的mRNA拼接中发挥着不同的作用.
相关概念视频
Structure-Activity Relationships and Drug Design
1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
MAPK Signaling Cascades
6.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.0K
Assembly of Signaling Complexes
5.9K
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
5.9K
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K


